Key result
Large RCT protocol evaluates oral magnesium citrate for preventing preterm birth and maternal morbidity.
RCT (n=3,000)
Double-blind
Randomized (2:1 ratio, 2000 vs 1000)
Yes
Answers are grounded in this paper and cite their sources.
BACKGROUND: Preterm birth is the leading cause of infant mortality globally, including Brazil. We will evaluate whether oral magnesium citrate reduces the risk of placental dysfunction and its negative consequences for both the fetus and mother, which, in turn, should reduce the need for indicated preterm delivery. METHODS/DESIGN: We will complete a multicenter, randomized double-blind clinical trial comparing oral magnesium citrate 150 mg twice daily (n = 2000 women) to matched placebo (n = 1000 women), starting at 121/7 to 206/7 weeks gestation and continued until delivery. We will include women at higher risk for placental dysfunction, based on clinical factors from a prior pregnancy (e.g., prior preterm delivery, stillbirth or preeclampsia) or the current pregnancy (e.g., chronic hypertension, pre-pregnancy diabetes mellitus, maternal age > 35 years or pre-pregnancy maternal body mass index > 30 kg/m2). The primary perinatal outcome is a composite of preterm birth < 37 weeks gestation, stillbirth > 20 weeks gestation, neonatal death < 28 days, or SGA birthweight < 3rd percentile. The primary composite maternal outcome is preeclampsia arising < 37 weeks gestation, severe non-proteinuric hypertension arising < 37 weeks gestation, placental abruption, maternal stroke during pregnancy or ≤ 7 days after delivery, or maternal death during pregnancy or ≤ 7 days after delivery. DISCUSSION: The results of this randomized clinical trial may be especially relevant in low and middle income countries that have high rates of prematurity and limited resources for acute newborn and maternal care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02032186, registered December 19, 2013.
No takes yet. Share an insight, caveat, or question.
Alves et al. (2014) conducted an RCT in Pregnancy at higher risk for placental dysfunction and preterm birth (n=3,000). Oral magnesium citrate vs. Matched placebo was evaluated on Primary perinatal composite (preterm birth <37 weeks, stillbirth >20 weeks, neonatal death <28 days, or SGA birthweight <3rd percentile) and primary maternal composite (preeclampsia <37 weeks, severe non-proteinuric hypertension <37 weeks, placental abruption, or maternal stroke/death during pregnancy or ≤7 days postpartum). Oral magnesium citrate twice daily vs placebo is being evaluated in a study protocol for preventing preterm birth and morbidity; no results are reported yet.
Synapse has enriched 10 related papers. Consider them for comparative context: